Category Archives: Recent News

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same ...

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platform Bria-Pros+ is capable of activating ...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response ...

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases ...

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s ...

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. ...

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

BriaCell’s Bria-IMT ™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning ...

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital ...

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS(TM) IND

BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast ...